Long-term drug treatment in multiple sclerosis: safety success and concerns.
Dejan JakimovskiCaila B VaughnSvetlana EckertRobert ZivadinovBianca Weinstock-GuttmanPublished in: Expert opinion on drug safety (2020)
Long-term extension trials, large observational studies and real-world databases allow detection of rare and potentially serious adverse events. Two-year-long trials are unable to fully capture the positive and negative effects of immune system modulation and reconstitution. DMT-based monitoring programs can provide greater insights regarding safe use of MS medications in different patient populations and clinical settings. During the process of shared DMT decision, both MS care providers and their patients should be aware of an ever-expanding number of drug-based adverse events and their influence on the risk-benefit analysis.
Keyphrases
- multiple sclerosis
- mass spectrometry
- end stage renal disease
- ms ms
- healthcare
- ejection fraction
- newly diagnosed
- public health
- palliative care
- prognostic factors
- peritoneal dialysis
- case report
- machine learning
- decision making
- affordable care act
- chronic pain
- patient reported outcomes
- combination therapy
- replacement therapy
- label free